Teva Pharmaceutical Industries Target of Unusually Large Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of unusually large options trading activity on Monday. Stock investors purchased 37,691 put options on the stock. This is an increase of 38% compared to the typical volume of 27,275 put options.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the stock. DGS Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares during the period. Franklin Resources Inc. boosted its position in Teva Pharmaceutical Industries by 141.7% in the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock worth $2,674,000 after purchasing an additional 90,920 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Sanctuary Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after buying an additional 664 shares in the last quarter. Finally, TCW Group Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $1,286,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 0.5 %

NYSE:TEVA traded up $0.12 during midday trading on Monday, reaching $22.21. 7,436,313 shares of the stock traded hands, compared to its average volume of 9,438,637. The stock has a market capitalization of $25.16 billion, a P/E ratio of -26.13, a PEG ratio of 0.99 and a beta of 0.79. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a 12 month low of $10.34 and a 12 month high of $22.25. The company has a fifty day moving average of $17.79 and a 200 day moving average of $17.52.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.